Otsuka bids for a seat at the conjugate table
The acquisition of Araris follows a 2023 discovery collaboration.
Sutro calls time on folate
At long last luvelta-T is shelved, and Sutro seeks a new focus.
ALX plays the conjugate card
Could a new ADC project distract attention away from evorpacept?
GSK and Hansoh press on despite Pfizer’s exit
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
FDA red and green lights: February 2025
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
